---
layout: page
title: >-
  IBD Stock Of The Day Breaks Out On Strong Quarterly Report, Outlook
image: /assets/img/stock-of-the-day/2018-11-01.jpg
date: 2018-11-01 16:19 -0700
author: ALLISON GATLIN
---






**Repligen** ([RGEN](https://research.investors.com/quote.aspx?symbol=RGEN)) is the [IBD Stock Of The Day](https://www.investors.com/research/ibd-stock-of-the-day/) after the bioprocessing company broke out Thursday from an early-stage base on its 15th straight quarter of double-digit sales growth.




On the [stock market today](https://www.investors.com/market-trend/stock-market-today/stock-market-today-market-trends-best-stocks-buy-watch/), Repligen stock flew 17.2%, to 63.55, after breaking out with a [buy point](https://www.investors.com/how-to-invest/investors-corner/chart-reading-basics-how-a-buy-point-marks-a-time-of-opportunity/) of 59.09.


Repligen stock has climbed more than 49% year to date, outperforming the Medical-Products industry group, which has risen north of 21%.


Repligen makes products used by biotech companies to develop biological drugs. These drugs use organic materials. Repligen makes protein products, chromatography and filtration products. Chromatography is a specific process of separating a mixture.





IBD Newsletters
---------------


#### Get exclusive IBD analysis and actionable news daily.




SIGN UP NOW!





IBD Newsletters
---------------


#### Get exclusive IBD analysis and actionable news daily.




* Financial Advisor Update
* How To Invest
* Market Prep
* Tech Report



Please enter a valid email address
Please select a newsletter


GO
Get these newsletters delivered to your inbox & more info about our products & services. [Privacy Policy](https://www.investors.com/investors-business-daily-privacy-policy/) & [Terms of Use](https://www.investors.com/home/investors-business-daily-inc-terms-of-use/)



x



Thank You!
----------


#### You will now receive IBD Newsletters




ALL DONE!




Something Went Wrong!
---------------------


#### Please contact customer service




CLOSE




Quarterly Metrics Top Views
---------------------------


During the third quarter, [Repligen earned](https://www.snl.com/IRW/file/4325751/Index?KeyFile=395589744) 20 cents per share, on an adjusted basis, up from 15 cents per share in the year-earlier period, Repligen said in a news release. That beat analyst estimates as polled by FactSet for 18 cents per share.


Total sales grew 35% to $49.5 million, hitting a record and topping expectations for $46.7 million. Organically, sales increased 24%. In constant currency, revenue growth was 36%. Repligen's sales have grown by double digits since March 2015.


Adjusted earnings also returned to growth in the third quarter after declining 20% in the second quarter. Repligen's adjusted earnings have growth by double digits in nine out of the past 10 quarters.


Repligen also raised its guidance for 2018 sales by $5 million at the midpoint. The firm now sees total sales of $191 million to $194 million. The new outlook topped analysts' estimate for $187.9 million.


On an adjusted basis, Repligen expects to earn 71-75 cents per share, up from its prior guide for 69-73 cents. The consensus had modeled 71 cents.


Repligen Stock Has High Ratings
-------------------------------


Repligen stock is highly rated among its peers. It has a [Relative Strength Rating](https://research.investors.com/stock-lists/relative-strength-at-new-high/) of 96 out of a best-possible 99. Out of 118 medical-products stocks, 23 have RS Ratings of 95 or above, which is considered a strong indicator of a stock's strength.


The company also has a [Composite Rating](https://www.investors.com/how-to-invest/investors-corner/the-ibd-composite-rating/) of 91 out of a best-possible 99, meaning it trades in the top 9% of all stocks in terms of key growth metrics.


Medical-products stocks are ranked No. 13 out of 197 industry groups tracked by Investor's Business Daily. Big group names by market cap include **Medtronic** ([MDT](https://research.investors.com/quote.aspx?symbol=MDT)), **Stryker** ([SYK](https://research.investors.com/quote.aspx?symbol=SYK)) and **Boston Scientific** ([BSX](https://research.investors.com/quote.aspx?symbol=BSX)).


**YOU MIGHT ALSO LIKE:**


[Estate Planning Checklist: Easy Stress-Free Steps For Getting Organized](https://www.investors.com/etfs-and-funds/retirement/estate-planning-checklist-easy-steps/)


[Looking For The Next Nvidia? Start With These 3 Steps](https://www.investors.com/research/ibd-stock-analysis/how-to-invest-in-the-stock-market-start-with-a-simple-routine/)


[How Much Money Do You Need To Start Investing In Stocks?](https://www.investors.com/how-to-invest/investors-corner/how-much-money-do-you-need-to-start-investing/)




